Trial reportJournal of the American Heart Association2025
A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04174456 (Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial metabolism plays an important role in maintaining cardiac function. Patients with dilated cardiomyopathy exhibit alterations in myocardial metabolism characterized by increased myocardial glucose metabolism. This study aimed to evaluate effects on myocardial metabolism of the angiotensin II receptor blockers olmesartan and valsartan in patients with dilated cardiomyopathy. We hypothesized that olmesartan, owing to its stronger and longer-lasting angiotensin II receptor blockade, would lead to a greater reduction in myocardial glucose metabolism compared with valsartan.
methodsOVOID (A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy) was a multicenter, randomized controlled trial involving 44 patients with New York Heart Association classes II through IV dilated cardiomyopathy. Participants were randomized 1:1 to receive olmesartan (20 mg once daily) or valsartan (160 mg twice daily) for 6 months, in addition to standard care. The primary outcome was myocardial glucose metabolism measured by standardized uptake value ratio at 6 months after treatment. To measure standardized uptake value ratio,
resultsBaseline clinical characteristics and standardized uptake value ratio were not significantly different between the 2 groups. The average left ventricular ejection fraction was 25.1%±7.8% at baseline, with significant improvement in both groups after 6 months, though with no difference between them. At 6 months, the standardized uptake value ratio value was significantly lower in the olmesartan group than that in the valsartan (3.76±2.00 versus 5.76±3.10;
conclusionsSix months of olmesartan therapy significantly decreased myocardial glucose metabolism in dilated cardiomyopathy patients compared with valsartan therapy for 6 months. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04174456.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.